Bridging the Chasm: India Urged to Overhaul Cancer Care Access and Affordability

DNI SUMMARY — KEY POINTS

• Leading Indian oncologists and health experts are advocating for a unified national strategy to resolve the significant disparity between innovative cancer therapies and actual patient access.
• The World Health Organisation warns that annual cancer cases worldwide could climb to 35 million by 2050 if structural inequities in diagnosis and treatment remain unaddressed.
• Financial toxicity serves as a primary barrier in India where medical expenses often force families into extreme debt or cause patients to abandon evidence-based treatment regimens entirely.
• Government policy initiatives like the Union Budget 2026-27 provide customs duty exemptions for drugs, yet experts maintain that infrastructure and early screening remain critical gaps.
• The Indian Cancer Society and other advocacy groups are pushing for the integration of high-value, cost-effective therapies into national health schemes to maximize public survival rates.

India is currently facing a critical juncture in its oncology landscape as medical leaders and public health experts call for a cohesive national strategy to bridge the widening gap in cancer care. While scientific breakthroughs have revolutionized treatment options globally, the practical availability of these therapies for the average citizen remains severely constrained by high costs and unequal infrastructure. During recent discussions hosted by the Indian Cancer Society, stakeholders emphasized that the path forward requires not just innovation but a fundamental shift toward making these life-saving medical advancements accessible to every eligible patient across the diverse socio-economic spectrum of the country.

Crisis of Healthcare Equity

The escalating cancer burden represents a significant economic and social crisis that demands urgent attention from policymakers and healthcare providers. With incidence rates projected to rise sharply, the system is struggling to manage both the surge in new cases and the high costs associated with modern treatments. World Health Organisation data highlights a sobering reality where geography and income levels remain the primary determinants of survival outcomes. To mitigate these disparities, experts argue that the country must leverage existing frameworks to ensure that financial barriers do not dictate the quality of care or the ultimate survival probability of a patient.

Financial toxicity is a pervasive issue that forces many families to make devastating choices, often leading to the discontinuation of treatment in favor of unproven alternatives. This economic strain is deeply intertwined with the high prevalence of out-of-pocket expenditure, which accounts for a significant portion of healthcare costs in the nation. Medical directors at prominent institutions like BALCO Medical Centre have observed that when patients drift toward traditional healers due to the prohibitive cost of modern care, preventable conditions quickly evolve into advanced, incurable stages. This cycle of financial and medical decline underscores the desperate need for more robust insurance coverage and state-sponsored assistance.

Mitigating Financial Toxicity Risks

Standardizing healthcare infrastructure and integrating evidence-based diagnostic tools is essential for reducing the current burden on tertiary care facilities. The current reliance on private financing creates a lopsided distribution of resources, leaving remote populations at a disadvantage regarding early detection and continuous care. By incorporating health technology assessments into the national policy framework, the government can effectively prioritize therapies that offer the most significant public health benefits. Ayushman Bharat serves as a vital platform for this integration, potentially offering a pathway to lower the out-of-pocket expenses that currently cripple middle- and lower-income households during long-term cancer management.

Rehabilitation remains a frequently overlooked component of the oncology pathway, yet it is crucial for ensuring that survivors maintain their quality of life after treatment. Many patients suffer from chronic impairments, such as nerve damage or reduced mobility, which can significantly hinder their ability to return to the workforce or maintain personal independence. Although government initiatives are beginning to focus on localizing care through Day Care Cancer Centres, there is an ongoing need to incorporate holistic rehabilitation services as a core pillar of the national cancer control agenda rather than treating it as a peripheral luxury service.

Integrating Holistic Rehabilitation Services

Scientific evaluation must guide the adoption of new medicines to ensure that limited public funds are directed toward the most impactful interventions. Relying on real-world evidence and clinical data will allow the healthcare system to transition from reactive care to a more proactive, data-driven approach. Public health experts suggest that by streamlining the approval and implementation of affordable biosimilars, India can significantly reduce the cost of treatment while maintaining high clinical standards. This strategic focus ensures that scientific progress translates directly into meaningful health gains for the largest possible number of citizens across all states.

The push for early detection and rigorous screening programs is paramount to preventing the progression of the disease to unmanageable stages. Vaccination campaigns against high-risk factors, combined with organized community outreach, serve as the first line of defense in reducing the long-term cancer burden. Organizations like the Indian Council of Medical Research continue to play a pivotal role in tracking trends and gathering the data necessary for informed policy decisions. Sustained investment in these preventive measures is widely viewed as the most sustainable way to lower the overall incidence of the disease in the coming decades.

Future Path for Cancer Care

Moving forward, the collaborative effort between public institutions and the private sector will define the success of India's cancer care mission. Through the newly proposed Biopharma Shakti framework and expanded public-private partnerships, there is potential to scale diagnostic capabilities and drug manufacturing to meet the growing demand. The ultimate objective remains clear: to ensure that the advancements in oncology are not gated by financial status, but are instead accessible components of a standardized health system. By prioritizing the patient experience, India can pave a sustainable path toward a more equitable and cancer-resilient future for all its people.